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OBJECTIVES: To estimate 6 months costs and quality of life (QoL) of patients with 
moderate to very severe COPD (GOLD criteria) who experienced a COPD exacerba-
tion in comparison with control groups of similar COPD severity without exacerba-
tion. METHODS: COPD in- and outpatients (Grade II  28; III  31; IV  31) with 
exacerbation (EXA-groups) were assessed retrospectively (3 month prior to exacerba-
tion) and prospectively (3 month after exacerbation) and compared to controls (CO-
groups) of similar disease severity but stable health (3 month retrospective assessment). 
Direct costs included hospitalization, outpatient visits, laboratory tests, imaging, medi-
cation and rehabilitation. Indirect costs included short and long term disability pay-
ments. All costs were converted to a period of 180 days; health care costs used 2008 
prices from the payer’s perspective. A validated translation of the EQ5D was com-
pleted at inclusion day (all groups) and at ﬁnal visit (EXA-groups). RESULTS: About 
18% of grade-II and 75% grade-IV exacerbations were hospitalized, resulting in 
increased costs with COPD severity (6-months median: Grade II  a846; III  a2159; 
IV  a3856; all p  0.05). Median 6-months costs in CO-groups were lower, although 
increasing from moderate to very severe COPD (Grade II  a567; III  a1610; IV  
a2084; all p  0.05). Exacerbation accounted for 8% (grade-II) to 31% (grade-IV) of 
total 6-months costs. Mean EQ5D utilities in the CO-groups and in the EXA-groups 
at ﬁnal visit were comparable (moderate: 0.589 vs.0.636; severe: 0.623 vs. 0.591; very 
severe: 0.524 vs. 0.479; NS). Mean EXA-groups utilities at inclusion were signiﬁcantly 
lower compared to ﬁnal assessment (p  0.001) and decreasing with COPD severity 
(moderate: 0.524; severe: 0.390; very severe: 0.230), reﬂecting QoL impairment during 
COPD exacerbation and natural disease course. CONCLUSIONS: The BURDEN 
study conﬁrmed for the Czech Republic a considerable economic burden of COPD. 
In accordance with international literature we found increased costs and decreased 
QoL for 1) COPD exacerbation vs. control in stable state, and 2) COPD 
progression.
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Suh DC1, Kim CM2, Kwon JW1, Choi IS1, Yang JH1, Barone JA1
1Rutgers University, Piscataway, NJ, USA, 2Catholic University, Seoul, South Korea
OBJECTIVES: To estimate annual medical and productivity costs attributable to 
obesity in working U.S. adults with asthma. METHODS: This study applied a cross 
sectional design using the 2003–2006 Medical Expenditure Panel Survey. Asthma 
patients (18–64 years old) were identiﬁed by self reported diagnosis or ICD-9-CM 
code of 493. Patients with pregnancy, malignancy, kidney dialysis, immunodeﬁciency, 
chronic obstructive pulmonary disease, low body-mass-index(BMI) 18.5, or unem-
ployed status were excluded. To investigate the impact of obesity, patients were clas-
siﬁed as normal (BMI: 18.5- 25) or obese(BMI: q30). Medical costs included all 
medical costs except for treatment costs of dental problems or injuries. Medical costs 
were estimated using a generalized linear model with a log link function and a gamma 
distribution. Loss of productivity was measured through the loss of workdays due to 
illness or injury for one year and valued using the hourly wage. Values of productivity 
loss were estimated using the two-part model. Costs attributable to obesity were esti-
mated by the differences between actual and expected costs, holding the distribution 
of covariates obtained from the normal and obese patients in the model. All costs were 
converted to 2008 U.S. dollars using price indices. RESULTS: Among a total of identi-
ﬁed 4,317 working adults with asthma, prevalence of normal weight is 34% while 
obese was 32%. The costs attributable to obesity were $2,384 (95%CI:$2,232–
$2,536) for total medical treatment costs and $215 (95%CI $189–$241) for costs 
associated with productivity loss. The missed working days attributable to obesity 
were 2.4 days/year/patient (95%CI:2.1–2.7 days). The attributable costs to medical 
and productivity loss increased as patients became older or were female patients. 
CONCLUSIONS: Obese asthma patients have signiﬁcantly higher costs associated 
with medical treatment and greater productivity loss compared to normal-weight 
asthma patients. Education aimed at weight control in asthma patients could result in 
a signiﬁcant reduction in the economic burden of treating asthma patients and enhance 
productivity.
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OBJECTIVES: To compare maintenance (using the ﬁxed combination of Salmeterol 
 Fluticasone; SAL/FP) and symptomatic (no maintenance) treatments of asthma with 
a developed transparent pharmacoeconomic model. METHODS: Lack of asthma 
control leads to unscheduled resources utilization and so growth of total cost (direct 
and indirect). Algorithm of OPTIMA model calculation includes 4 steps: 1) Analysis 
of weighted average cost of maintenance medicines based on dosing, average prices 
in reimbursement, and dose distribution in assessing population, and 2) Assessment 
of cost associated with controlled and uncontrolled asthma based on number of 
unscheduled resources utilization (emergency service, outpatient visits, inpatient stay, 
and work-off days) and their unit-cost (sources–current Russian legislation, RosStat 
data) as well as QoL. 3) Detection of frequency of controlled/uncontrolled asthma in 
arms based on clinical trials data. 4) Calculation of total cost in arms (cost of drug  
% controlled * cost of controlled  % uncontrolled * cost of uncontrolled) and amount 
of saving. RESULTS: Weighted average cost of SAL/FP in Russia was 1 672 Rub 
(~ 40 EUR) per month. Cost associated with controlled and uncontrolled asthma were 
320 Rub and 62,753 Rub (~a8 and a1,400) per patient per year, respectively; QoL 
scores were 0.75 and 0.49 respectiverly. Frequency of controlled asthma in SAL/FP 
arm was 75% (GOAL study) and so 25% patients were uncontrolled. Assumed fre-
quency of controlled asthma using symptomatic treatment instead of SAL/FP  5%. 
Total costs were 35 991 Rub and 59,632 Rub (~a850 and a,1400) in maintenance and 
symptomatic arms, respectively; average QoL score were 69% and 50.3%. CONCLU-
SIONS: The model allows transparent comparisons of different asthma treatment 
approaches. Maintenance treatment with SAL/FP was superior (less cost and higher 
QoL) to symptomatic treatment.
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COST EFFECTIVENESS OF VARENICLINE COMPARED WITH EXISTING 
SMOKING CESSATION STRATEGIES IN HONG KONG
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OBJECTIVES: Smoking causes serious public health problems in Hong Kong. Effec-
tive smoking cessation strategies are required in order to cut public health budgets 
and save lives. The aim of this study is to estimate the cost effectiveness of a new 
smoking-cessation agent varenicline compared with the traditional strategies including 
bupropion, nicotine replacement treatment (NRT) and unaided cessation in Hong 
Kong. METHODS: A previously published Markov state-transition projection model 
was employed to estimate the life-long costs and effects of smoking cessation using 
varenicline, bupropion, NRT and unaided cessation from a societal perspective. Based 
on local epidemiology, a cohort of adult smokers was assumed to have a one-time 
quit attempt and was grouped by their genders and ages. Management costs and utili-
ties of ﬁve smoking related diseases including chronic obstructive pulmonary disease 
(COPD), lung cancer, coronary heart disease (CHD), stroke and asthma were studied. 
The participants of each group experienced different transition probabilities based on 
their age and disease-speciﬁc morbidity and mortality rates. Vital statistics, disease-
related morbidity and mortality rates were obtained from government statistics. Out-
comes of the study in terms of beneﬁts and costs were discounted at 5% after the ﬁrst 
year of the study. Probabilistic sensitivity analysis was performed to assess the impact 
on the model outputs of uncertainty in certain model parameters including efﬁcacies 
of the smoking cessation strategies, morbidity costs and morbidity utilities. RESULTS: 
Varenicline dominated among all the strategies with HKD106,573 (US$13,663, 
HKD7.8  USD1)/QALY when compared with bupropion; HKD246,042 
(US$31,544)/QALY with NRT and HKD41,426 (US$5,311)/ QALY with unaided 
cessation. The probabilities of varenicline being cost-effective were 77.9% when 
compared with bupropion, 69.3% with NRT and 88.3% with unaided cessation, at 
a willingness to pay of HKD50,000 (US$6410)/QALY. CONCLUSIONS: From the 
current study, varenicline appears to be a cost-effective smoking-cessation strategy 
when compared with the other existing strategies in Hong Kong.
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OBJECTIVES: To calculate the cost-effectiveness of palivizumab for the prevention 
of respiratory syncytial virus (RSV) hospitalization by risk group, using real-world 
cost and incidence estimates. METHODS: Decision trees were used to calculate 
incremental cost effectiveness ratios (ICERs) as the direct medical cost required to 
prevent one RSV-related hospitalization within 8 risk groups based on indication. Risk 
groups were deﬁned by age and combinations of comorbid conditions (chronic lung 
disease [CLD], congenital heart disease [CHD], or prematurity up to 32 weeks’ ges-
tational age), in accordance with treatment guidelines. Cost and incidence parameters 
were derived from Florida Medicaid claims data (October 2004 to March 2005) using 
ICD-9 and national drug codes; palivizumab effectiveness was estimated from clinical 
trial data. RESULTS: Among 611,451 infant-months, 9,805 had claims for palivi-
zumab. Mean cost for a single dose ranged from $1347 [95% conﬁdence interval (CI): 
1336–1358] for infants under 6 months to $2096 [CI: 2081–2110] for children 1–2 
years of age. Seasonal 6-month RSV hospitalization rate ranged from 1.25% [CI: 
0.6–2.0] in children without indication to 8.13% [CI: 4.3–13.9] in premature infants 
with CHD. ICERs for palivizumab prophylaxis ranged from $246,719 [CI: 109,376–
877,173] for premature infants up to 6 months old to $1,796,002 [CI: 656,705–
9,910,719] for infants without indication. Having at least one indication resulted 
in ICER of $698,227 [CI: 290,981–2,475,180] for children 2 years of age. By com-
parison, the mean cost for RSV-related hospitalizations ranged from $4,111 [CI: 
3,891–4,330] for children without indication to $9816 [CI: 8,904–10,727] for chil-
dren with CLD. CONCLUSIONS: ICERs for palivizumab were found to be high, with 
